α2-agonist versus α1-antagonist in mild-to-moderate hypertension: Comparison of transdermal clonidine and terazosin monotherapies

American Journal of Therapeutics

Volumn 4, Issue 1, 1997, Pages 9-15

  Harris, Stuart I ^a,b   Alvarez, Celina ^a  

^a South Florida Unavailability Clinic Inc   (United States)

^b SeaView Research   (United States)

Author keywords

clonidine; hypertension; terazosin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; TERAZOSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION; XEROSTOMIA;

EID: 0030937712     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199701000-00003     Document Type: Article

References (18)

1. 2-adrenoceptor agonists for systemic hypertension. Am J Cardiol 1988;61:1D-5D.
2. Louis WJ, McNeil JJ, Anavekar SN, Conway EL, Workman B, Howes LG, Drummer OH, Jarrott B: Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents. J Cardiovasc Pharmacol 1987;10(Suppl 12):S100-103.
3. Khoury AF, Kaplan NM: α-blocker therapy of hypertension. An unfulfilled promise. JAMA 1991;266:394-398.
4. Karlberg BE, Lins L-E, Rössner S: Clonidine in mild to moderate hypertension: Effects on blood pressure and serum lipoproteins. J Hypertens 1985;3(Suppl 4):S69-71.
5. Nilsson-Ehle P, Ekberg M, Fridström P, Ursing D, Lins L-E: Lipoproteins and metabolic control in hypertensive Type II diabetics treated with clonidine. Acta Med Scand 1988;244:131-134.
6. Lowenthal DT, Saris S, Paran E, Cristal N, Sharif K, Bies C, Pagan T: Efficacy of clonidine, a transdermal therapeutic system: The international clinical trial experience. Am Heart J 1986;112:893-900.
7. Hollifield J: Clinical acceptability of transdermal clonidine: A large-scale evaluation by practitioners. Am Heart J 1986;112:900-906.
8. Burris JF, Papademetriou V, Wallin JD, Cook ME, Weidler DJ: Therapeutic adherence in the elderly: Transdermal clonidine compared to oral verapamil for hypertension. Am J Med 1991;91(Suppl 1A):22S-28S.
9. Branche GC, Batts JM, Dowdy VM, Field LS, Francis CK: Improving compliance in an inner-city hypertensive patient population. Am J Med 1991;91(Suppl 1A):37S-41S.
10. Hubbell FA, Weber MA, Drayer JIM, Rose DE: Comparative antihypertensive and endocrinologie effects of clonidine and prazosin in patients with essential hypertension. South Med J 1984;77:1264-1268.
11. Guthrie GP, Kotchen TA: Effects of prazosin and clonidine on sympathetic and baroreflex function in patients with essential hypertension. J Clin Pharmacol 1983;23: 348-354.
12. Kirkendall WM, Hammond JJ, Thomas JC, Overturf ML, Zama A: Prazosin and clonidine for moderately severe hypertension. JAMA 1978;240:2553-2556.
13. Prisant LM, Bottini B, DiPiro JT, Carr AA: Novel drug delivery systems for hypertension. Am J Med 1992;93(Suppl 2A):45S-55S.
14. Houston MC: New insights and approaches to reduce end-organ damage in the treatment of hypertension: Subsets of hypertension approach. Am Heart J 1992;123: 1337-1367.
15. Millar-Craig MW, Bishop CN, Raftery EB: Circadian variation of blood pressure. Lancet 1978;1:795-797.
16. AMA Council on Scientific Affairs: Hispanic health in the United States. JAMA 1991;265:248-252.
17. Francis CK: Hypertension, cardiac disease, and compliance in minority patients. Am J Med 1991;91(Suppl 1A): 29S-36S.
18. McMahon FG, Jain AK, Vargas R, Fillingim J: A double-blind comparison of transdermal clonidine and oral captopril in essential hypertension. Clin Ther 1990;12:88-100.